4-(2-羟基苯基)丁酸甲酯 | 93108-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-(2-羟基苯基)丁酸甲酯
• 英文名称: methyl 4-(2-hydroxyphenyl)butanoate
• 英文别名: methyl 4-(2-hydroxyphenyl)-butyrate
• CAS: 93108-07-7
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: UUMPJJUSWJCWJU-UHFFFAOYSA-N

物化性质

• 沸点：
  310.1±25.0 °C(Predicted)
• 密度：
  1.118±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-(2-羟基苯基)丁酸甲酯 在 sodium hydroxide 作用下， 生成 4,5-二氢苯并[B]氧杂卓-2(3H)-酮
  参考文献：
  名称：

  DE562827

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(2-羟基苯基)丁酸 在 硫酸 作用下， 以 甲醇 为溶剂， 生成 4-(2-羟基苯基)丁酸甲酯
  参考文献：
  名称：

  Hydroformylation of acyclic monoethylenically unsaturated compounds to corresponding terminal aldehydes

  摘要：

  一种利用第VIII族过渡金属和选择的多齿膦配体将无环单乙烯不饱和化合物水甲醛化为相应的末端醛的方法。

  公开号：

  US06307107B1

文献信息

• A metal-free desulfurizing radical reductive C–C coupling of thiols and alkenes
  作者：Qixue Qin、Weijing Wang、Cheng Zhang、Song Song、Ning Jiao

  DOI：10.1039/c9cc05378f

  日期：——

  An intermolecular reductive C–C coupling of electrophilic alkyl radicals and alkenes has been developed. Thiols were used as both hydrogen-donating reagents and alkyl radical precursors in the presence of triethyl phosphite and radical initiator. A wide range of alkenes, including styrenes, and aliphatic olefins were well tolerated in this transformation. Mechanistic studies indicated that a phosphite

  已经开发出亲电烷基和烯烃的分子间还原性C–C偶联。在亚磷酸三乙酯和自由基引发剂的存在下，硫醇既用作给氢试剂，又用作烷基自由基前体。在这种转化中，包括苯乙烯和脂肪族烯烃在内的各种烯烃均具有良好的耐受性。机理研究表明，亚磷酸酯促进了硫醇的自由基脱硫，以进入亲电子烷基自由基，并且自由基链的扩散过程可能与这种转化有关。
• [EN] METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES<br/>[FR] PROCÉDÉS DE PRODUCTION DU BÉRAPROST ET SES DÉRIVÉS
  申请人：LUNG BIOTECHNOLOGY PBC

  公开号：WO2015179427A1

  公开（公告）日：2015-11-26

  The present invention is directed to methods for preparing Beraprost and novel synthetic intermediates for Beraprost. In one aspect, a process is provided to produce a pharmaceutical compound represented by the general Formula (I) via a radical cyclization route. The process is completed in fewer steps than the known synthetic methods and may be conducted to prepare commercially useful quantities. In another aspect, synthetic methods are provided for producing Beraprost and its derivatives,, which are stereoselective, efficient, scalable and economical. In another aspect, substantially isomerically pure compounds and intermediates are produced by the above processes.

  本发明涉及制备贝拉前列素（Beraprost）的方法以及贝拉前列素的新型合成中间体。在一个方面，提供了通过自由基环化路线生产一般式（I）代表的药物化合物的方法。该过程比已知的合成方法完成步骤更少，并可用于制备商业上有用的数量。在另一个方面，提供了用于生产贝拉前列素及其衍生物的合成方法，这些方法具有立体选择性，高效，可扩展和经济。在另一个方面，通过上述过程生产了基本异构纯化合物和中间体。
• BENZENE DERIVATIVE
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20210332009A1

  公开（公告）日：2021-10-28

  A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).

  通式（I）表示的化合物（在公式中，所有符号如描述中所述）或其盐具有强大的神经保护和/或修复活性，因此可用作神经病变的治疗剂（例如，慢性炎症性脱髓鞘性多发性神经病、吉兰-巴雷综合征、周围动脉炎、过敏性血管炎、糖尿病周围神经病变、神经卡压病变、与化疗药物治疗相关的周围神经病变，或与沙科-玛丽-图斯病相关的周围神经病变）。
• Carboxylic acid leukotriene B.sub.4 antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US05434186A1

  公开（公告）日：1995-07-18

  Compounds of the formula ##STR1## wherein X is O or CH.sub.2 ; Y is O, --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, or --OCH.sub.2 C.sub.6 H.sub.4 --; Z is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH-- or --C.tbd.C--; f, h, k, m and t, independently, are 0 or 1; n is an integer from 1 to 12; R.sup.1 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, or aralkyl; and A is B or --O--B, wherein B is a mono-, di- or tricyclic aromatic or heteroaromatic moiety substituted by the group --COR.sup.2, --(O).sub.t --(W).sub.s --COR.sup.2 or --(CH.dbd.CH).sub.p COR.sup.2 and which may also contain up to 4 additional substituents selected, independently, from the group consisting of halogen, cyano, lower alkyl, lower alkoxy, sulfonamido, alkanoyl, aroyl, --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, provided that no more than one of said substituents is --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, and wherein E is COR.sup.2 or R.sup.2, W is --CR.sup.3 R.sup.4 --, Q is O or carbonyl, p is an integer from 1 to 2, s and s', independently, are an integer from 1-12, s" and s'", independently, are an integer from 0 to 12, C.sub.6 H.sub.4 is a 1,2-, 1,3-, or 1,4-phenylene moiety, and R.sup.2 is hydroxy, lower alkoxy or NR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4, each occurence, independently, are hydrogen or lower alkyl, their geometric and optical isomers and, when R.sup.2 is hydroxy, pharmaceutically acceptable salts thereof with bases. The compounds of formula I are potent leukotriene B.sub.4 antagonists and are therefore useful in the treatment of inflammatory diseases, such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, ischemia/reperfusion injury, and trauma induced inflammation, such as spinal cord injury.

  公式I的化合物为##STR1##其中X为O或CH.sub.2; Y为O，--CH.sub.2 --CH.sub.2 --，--CH.dbd.CH--，--C.tbd.C--或--OCH.sub.2 C.sub.6 H.sub.4 --; Z为--CH.sub.2 --CH.sub.2 --，--CH.dbd.CH--或--C.tbd.C--; f，h，k，m和t分别为0或1; n为1至12的整数; R.sup.1为氢，低烷基，低烯基，环烷基或芳基烷基; A为B或--O--B，其中B是被基团--COR.sup.2，--(O).sub.t --(W).sub.s --COR.sup.2或--(CH.dbd.CH).sub.p COR.sup.2取代的单环、双环或三环芳香或杂芳基，可以还含有最多4个附加取代基，独立地从卤素，氰基，低烷基，低烷氧基，磺酰胺基，脂肪酰基，芳基，--(Q).sub.k --(W).sub.s' --E或--(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E中选择，只要不超过一个取代基是--(Q).sub.k --(W).sub.s' --E或--(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E，其中E为COR.sup.2或R.sup.2，W为--CR.sup.3 R.sup.4--，Q为O或羰基，p为1至2的整数，s和s'分别为1至12的整数，s"和s'"分别为0至12的整数，C.sub.6 H.sub.4为1,2-，1,3-或1,4-苯基基团，R.sup.2为羟基，低烷氧基或NR.sup.3 R.sup.4，其中R.sup.3和R.sup.4，每次出现，独立地为氢或低烷基，它们的几何和光学异构体以及当R.sup.2为羟基时，与碱形成的药学上可接受的盐。公式I的化合物是有效的白三烯B.sub.4拮抗剂，因此在治疗炎症性疾病，如牛皮癣，炎症性肠病，哮喘，过敏，关节炎，皮炎，痛风，肺部疾病，缺血/再灌注损伤以及创伤引起的炎症，如脊髓损伤方面有用。
• Carboxylic acid leukotriene B4 antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US05273999A1

  公开（公告）日：1993-12-28

  Compounds of the formula ##STR1## wherein X is O or CH.sub.2 ; Y is O, --CH.sub.2 --CH.sub.2, --CH.dbd.CH--, --C.tbd.C--, or --OCH.sub.2 C.sub.6 H.sub.4 --; Z is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH-- or --C.tbd.C--; f, h, k, m and t, independently, are 0 or 1; n is an integer from 1 to 12; R.sup.1 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, or aralkyl; and A is B or --O--B, wherein B is a mono-, di- or tricyclic aromatic or heteroaromatic moiety substituted by the group --COR.sup.2, --(O).sub.t --(W).sub.s --COR.sup.2 or --(CH.dbd.CH).sub.p COR.sup.2 and which may also contain up to 4 additional substituents selected, independently, from the group consisting of halogen, cyano, lower alkyl, lower alkoxy, sulfonamido, alkanoyl, aroyl, --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, provided that no more than one of said substituents is --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, and wherein E is COR.sup.2 or R.sup.2, W is --CR.sup.3 R.sup.4 --, Q is O or carbonyl, p is an integer from 1 to 2, s and s', independently, are an integer from 1-12, s" and s'", independently, are an integer from 0 to 12, C.sub.6 H.sub.4 is a 1,2-, 1,3-, or 1,4-phenylene moiety, and R.sup.2 is hydroxy, lower alkoxy or NR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4, each occurrence, independently, are hydrogen or lower alkyl, their geometric and optical isomers and, when R.sup.2 is hydroxy, pharmaceutically acceptable salts thereof with bases. The compounds of formula I are potent leukotriene B.sub.4 antagonists and are therefore useful in the treatment of inflammatory diseases, such as psoriasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, ischemia/reperfusion injury, and trauma induced inflammation, such as spinal cord injury.

  公式为##STR1##的化合物中，其中X为O或CH.sub.2；Y为O，--CH.sub.2--CH.sub.2，--CH.dbd.CH--，--C.tbd.C--或--OCH.sub.2C.sub.6H.sub.4--；Z为--CH.sub.2--CH.sub.2--，--CH.dbd.CH--或--C.tbd.C--；f，h，k，m和t分别为0或1；n为1至12的整数；R.sup.1为氢，低级烷基，低级烯基，环烷基或芳基烷基；A为B或--O--B，其中B是一个被羰基--COR.sup.2，--(O).sub.t--(W).sub.s--COR.sup.2或--(CH.dbd.CH).sub.pCOR.sup.2取代的单环，双环或三环芳香或杂芳香基团，并且还可以包含最多4个额外的取代基，独立地从卤素，氰基，低级烷基，低级烷氧基，磺酰胺基，烷酰基，芳酰基，--(Q).sub.k--(W).sub.s'--E或--(Q).sub.k--(W).sub.s"--C.sub.6H.sub.4--(W).sub.s'"--E中选择，前提是不超过一个取代基为--(Q).sub.k--(W).sub.s'--E或--(Q).sub.k--(W).sub.s"--C.sub.6H.sub.4--(W).sub.s'"--E，其中E为COR.sup.2或R.sup.2，W为--CR.sup.3R.sup.4--，Q为O或羰基，p为1至2的整数，s和s'独立地为1至12的整数，s"和s'"独立地为0至12的整数，C.sub.6H.sub.4为1,2-,1,3-或1,4-苯基基团，R.sup.2为羟基，低级烷氧基或NR.sup.3R.sup.4，其中R.sup.3和R.sup.4每次独立地为氢或低级烷基，它们的几何和光学异构体以及当R.sup.2为羟基时，与碱的药学上可接受的盐。公式I的化合物是有效的白三烯B.sub.4拮抗剂，因此在治疗炎症性疾病，如银屑病，炎症性肠病，哮喘，过敏，关节炎，皮炎，痛风，肺部疾病，缺血/再灌注损伤以及创伤引起的炎症，如脊髓损伤方面有用。